Sucampo Pharmaceuticals Inc
Most Recent
The Financial Performance of Sucampo Pharmaceuticals
Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.
Key Risks Facing Sucampo Pharmaceuticals in 2017
Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.
Sucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape
In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.
Sucampo Pharmaceuticals’ Research Pipeline in December 2017
Sucampo Pharmaceuticals (SCMP) recently completed a Phase 3 study for the alternate sprinkle formulation of Amitiza (lubiprostone) in adults with CIC (chronic idiopathic constipation).
Sucampo Pharmaceuticals’ Amitiza: Its Performance in 2017
Sucampo Pharmaceuticals has granted licenses to commercialize a generic or authorized generic of Amitiza in the United States to Par Pharmaceutical and Dr. Reddy’s Laboratories.
Agios Announces Data from Phase 2 Study of PK Deficiency
Agios Pharmaceuticals was one of the top performers among the small-cap segment within the iShares Nasdaq Biotechnology ETF (IBB) on June 13, 2016.
A Comparative Analysis of PTH and DWAQ
PTH and DWAQ have followed similar trends in 2015. PTH has a higher beta than DWAQ because it’s a pure sectoral equity fund, and its trend movement is more significant than DWAQ’s.
An Overview of PTH’s Pharmaceutical and Biotechnology Holdings
PTH is majorly invested in pharmaceutical companies, with 43.2% of its funds invested in pharmaceutical stocks. The biotechnology subsector comes next with a total share of 28.3%.
